TME is revolutionizing drug development…

With the industry now focusing their efforts on angiogenesis, hypoxia and targeting other factors in the microenvironment, the potential of the TME has been unlocked.

Designed in collaboration with Professor Michael Lisanti, founder of “The Autophagic Tumor Stroma Model of Cancer Metabolism”, Targeting the Tumor Microenvironment outlined exactly how knowledge of the TME can decrease attrition rates and improve the clinical success of cancer therapeutics. 

Thank you to everyone who attended the October 2012 Targeting the Tumor Microenvironment meeting! There were some really fantastic presentations and a great mix of participants which made for some fascinating discussions and meetings in networking breaks.

“Very interesting meeting, very effective workshops, wonderful atmosphere” Oncotest

“Great meeting, the strongest feature being the opportunity to network with colleagues”
Thomas Jefferson University

“This meeting was a great opportunity to see the latest advancements, especially in cancer in vivo models” Nippon Kayaku

“All the presentations were relevant and very helpful. Thanks for making the conference so worthwhile” Sanofi

With presentations, discussions and industry case studies from companies such as Pfizer, Johnson & Johnson, Genentech, Threshold, Sanofi and Eli Lilly, this meeting was designed to help the industry increase the therapeutic efficacy of cancer drugs.  

What was on the Agenda?

  • Groundbreaking keynote presentations on current TME from research leaders in the field: Michael Lisanti, Bob Weinberg and Richard Pestell  
  • Case studies from MIT and Genzyme, a Sanofi company on improving the clinical efficacy of your cancer therapeutics by targeting the tumor microenvironment 
  • Exploration of successful techniques with Pfizer and Johnson & Johnson to overcome the challenges of preclinical model development for the TME 
  • Practical lessons learnt from Bristol-Myers Squibb and Genentech on improving the success rate of therapeutics and overcoming resistance to cancer therapies  
  • IBM revealed how to expand your knowledge on computational modeling by discovering how they are designing novel algorithmic methods in order to model complex biological systems
  • Discussion on the use of biomarkers to successfully predict disease progression with Genentech who are developing effective oncology biomarkers 

Targeting the Tumor Microenvironment was the only meeting focusing on the commercial potential of this promising science.

Look out for more detail on next year's meeting, and save the date: 21st- 23rd October 2013!